A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types

Lawrence M. Kauvar, Keyi Liu, Minha Park, Neal DeChene, Robert Stephenson, Edgar Tenorio, Stote L. Ellsworth, Takako Tabata, Matthew Petitt, Mitsuru Tsuge, June Fang-Hoover, Stuart P. Adler, Xiaohong Cui, Michael A. McVoy, Lenore Pereira

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


Human cytomegalovirus (HCMV) is the most common infection causing poor outcomes among transplant recipients. Maternal infection and transplacental transmission are major causes of permanent birth defects. Although no active vaccines to prevent HCMV infection have been approved, passive immunization with HCMV-specific immunoglobulin has shown promise in the treatment of both transplant and congenital indications. Antibodies targeting the viral glycoprotein B (gB) surface protein are known to neutralize HCMV infectivity, with high-affinity binding being a desirable trait, both to compete with low-affinity antibodies that promote the transmission of virus across the placenta and to displace nonneutralizing antibodies binding nearby epitopes. Using a miniaturized screening technology to characterize secreted IgG from single human B lymphocytes, 30 antibodies directed against gB were previously cloned. The most potent clone, TRL345, is described here. Its measured affinity was 1 pM for the highly conserved site I of the AD-2 epitope of gB. Strain-independent neutralization was confirmed for 15 primary HCMV clinical isolates. TRL345 prevented HCMV infection of placental fibroblasts, smooth muscle cells, endothelial cells, and epithelial cells, and it inhibited postinfection HCMV spread in epithelial cells. The potential utility for preventing congenital transmission is supported by the blockage of HCMV infection of placental cell types central to virus transmission to the fetus, including differentiating cytotrophoblasts, trophoblast progenitor cells, and placental fibroblasts. Further, TRL345 was effective at controlling an ex vivo infection of human placental anchoring villi. TRL345 has been utilized on a commercial scale and is a candidate for clinical evaluation.

Original languageEnglish
Pages (from-to)1558-1568
Number of pages11
JournalAntimicrobial Agents and Chemotherapy
Issue number3
Publication statusPublished - Mar 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types'. Together they form a unique fingerprint.

Cite this